Liver CirrhosisVORTALNCT06169592
Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation
An observational study of Liver Cirrhosis and Liver Transplant; Complications, run by Republican Specialized Scientific and Practical Medical Center of Surgery Named After V. Vakhidov at 1 site in Uzbekistan.
Trial summary
The aim of the study is to improve the results of related transplantation of the right liver lobe by verifying the general predictors of the development of hemostatic system disorders and optimizing a comprehensive program for thrombohemorrhagic complications preventing. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Liver Cirrhosis, Liver Transplant; Complications
- What is being tested?
- Liver transplantation
- Type of treatment
- Surgery or procedure
- How many people
- 30 participants
- Where
- 1 siteUzbekistan
- Study dates
- 22 Apr 2022to 16 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with end stage liver cirrhosis who underwent living related liver transplantation.
Who may be able to join
- Age over 18 years and up to 70 years;
- Signed informed consent for inclusion to the study;
- End stage liver cirrhosis.
Who cannot join
- Pregnancy;
- Extrahepatic factors influencing systemic hemostasis;
- Concomitant hematological diseases affecting the hemostatic system;
- Severe concomitant disorders.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Uzbekistan1 site, 1 recruiting
- Recruiting
Republican specialized scientific and practical medical center of surgery named after academician V.Vakhidov
Tashkent, 100115
Azam Babadjanov, Professor, +998901751703, azam746@mail.ru
About this study
Official title: Verification of Prognostic Risk Factors of Thrombohemorrhagic Complications in Early Follow-up Period in Recipients After Living Related Liver Transplantation
The aim of the study is to improve the results of related transplantation of the right liver lobe by verifying the general predictors of the development of hemostatic system disorders and optimizing a comprehensive program for thrombohemorrhagic complications preventing.
- Conditions
- Liver Cirrhosis, Liver Transplant; Complications
- Being tested
- Liver transplantation
- Medical subject headings
- Liver Cirrhosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Liver transplantationProcedure or surgery
Related transplantation of the right lobe of the liver
| Study group | Role | What they receive |
|---|---|---|
| liver transplant group | Not described Receives: Procedure: Liver transplantation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Thrombosis of vascular anastomosis
Thrombosis of arterial or venous anastomosis after intervention
Measured: 1 month
Secondary outcomes (1)
Hemorrhagic complications
Any hemorrhagic complications after intervention
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2023
- Study start22 Apr 2022
- Primary completion14 Nov 2026 (estimated)
- Study completion16 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver CirrhosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Republican Specialized Scientific and Practical Medical Center of Surgery Named After V. Vakhidov
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Azam Babadjanov, Republican Specialized Scientific and Practical Medical Center of Surgery Named After V. Vakhidov
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06169592
- Sponsor's protocol ID
- 05122023
- Acronym
- VORTAL
- Status last verified
- Jul 2025
- First submitted
- 5 Dec 2023
- Last updated
- 30 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Verification of Prognostic Risk Factors of Thrombohemorrhagic Complications in Early Follow-up Period in Recipients After Living Related Liver Transplantation
- ClinicalTrials.gov ID
- NCT06169592
- Acronym / sponsor ID
- VORTAL / 05122023
- Conditions
- Liver Cirrhosis, Liver Transplant; Complications
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Republican Specialized Scientific and Practical Medical Center of Surgery Named After V. VakhidovUniversity, hospital or other
- Study start
- 22 Apr 2022 (actual)
- Primary completion
- 14 Nov 2026 (estimated)
- Study completion
- 16 Dec 2026 (estimated)
- First posted
- 13 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to improve the results of related transplantation of the right liver lobe by verifying the general predictors of the development of hemostatic system disorders and optimizing a comprehensive program for thrombohemorrhagic complications preventing.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| liver transplant group | – | Procedure: Liver transplantation |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with end stage liver cirrhosis who underwent living related liver transplantation.
Key inclusion criteria (3 listed)
- Age over 18 years and up to 70 years;
- Signed informed consent for inclusion to the study;
- End stage liver cirrhosis.
Key exclusion criteria (4 listed)
- Pregnancy;
- Extrahepatic factors influencing systemic hemostasis;
- Concomitant hematological diseases affecting the hemostatic system;
- Severe concomitant disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Liver transplantationRelated transplantation of the right lobe of the liver | Procedure or surgery | liver transplant group |
Primary outcome
Thrombosis of vascular anastomosis
Time frame: 1 month
Thrombosis of arterial or venous anastomosis after intervention
1 secondary outcome
Hemorrhagic complications
Time frame: 1 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Liver Cirrhosis
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
Recruiting
Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
Spontaneous Bacterial Peritonitis, Paracentesis
RecruitingObservational study
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
Liver Cirrhosis, Gastroesophageal Varices
Recruiting
CirrhosisRx CDS System
Cirrhosis, Decision Support Systems, Clinical
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Cirrhosis and Liver Transplant; Complications, run by Republican Specialized Scientific and Practical Medical Center of Surgery Named After V. Vakhidov at 1 site in Uzbekistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Uzbekistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Azam Babadjanov, Professor (+998901751703, azambabadjanov@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Thrombosis of vascular anastomosis (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2025; AzTrials last refreshed its copy on 8 Nov 2026.